The Department of Labor finalized a rule requiring PBMs to disclose compensation, rebates and spread payments to self-funded employer clients starting July 2027. Plan sponsors gain new visibility into PBM economics, and contract terms and audit rights may face renewed scrutiny.
A Department of Labor regulation expected Thursday would require PBMs to disclose drug prices and drugmaker payments to self-insured employer clients, effective July.
A Medicare rule reportedly targets drug copays and PBM payments, though the full text was unavailable for review.
The Hoboken City Council voted 7-2 to approve an $801,000 employer group Medicare Part D plan with Judi Rx.
Andel is expanding beyond GLP-1 management with CenterWell Pharmacy to help employers lower high-cost drug spending.
Optum Rx announced it is expanding access to menopause care, according to the headline; the page text was unavailable for details.
Reps. Matsui and Mann introduced a bipartisan bill aimed at the 340B drug pricing program.
IQVIA published findings on how large duplicate discounts are when 340B and Medicare Drug Price Negotiation (MFP) discounts overlap, the second part of its analysis.
A 340B contract pharmacy case has renewed scrutiny over the program's intent, according to a Targeted Oncology headline; full article text was unavailable.
The American Hospital Association published comments on the SUSTAIN 340B Act, a federal bill concerning the 340B drug pricing program.
U.S. employers are reportedly scaling back GLP-1 weight-loss drug coverage for 2027, according to a Traders Union report.
Employers are reportedly turning against their PBMs as healthcare costs approach a two-decade high, per Insurance Business.
A Quartz explainer outlines five key points about GLP-1 insurance coverage heading into 2026.
Employee Benefit News reports on why employers are reconsidering their pharmacy benefit managers; full article text was unavailable.